Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2744-2752

  Beissert, Tim ^a,d   Hundertmark, Alena ^a   Kaburova, Velina ^a   Travaglini, Lorena ^b   Mian, Afsar A ^a   Nervi, Clara ^b,c   Ruthardt, Martin ^a,d  

^a GOETHE UNIVERSITY   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Institute of Cell Biology and Tissue Engineering   (Italy)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

BCR ABL; Imatinib resistance; Molecular targeting; Oligomerization; Ph+ leukemia

Indexed keywords

ABELSON KINASE; AMINO TERMINAL TELOPEPTIDE; BCR ABL PROTEIN; DASATINIB; HELIX 2 PEPTIDE; IMATINIB; NILOTINIB; PEPTIDE DERIVATIVE; PROTEIN P185;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; LEUKEMIA; MOUSE; MUTATION; NONHUMAN; OLIGOMERIZATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS CELL TRANSFORMATION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BIOPOLYMERS; CELL LINE; DNA PRIMERS; FUSION PROTEINS, BCR-ABL; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES;

EID: 43049136596     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23467     Document Type: Article

References (32)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
2. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996;12:839-46.
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
4. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649-53.
5. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000;24:57-60.
6. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
7. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-8.
8. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
9. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
10. O'Dwyer ME, Mauro MJ, Druker BJ. STI571 as a targeted therapy for CML. Cancer Invest 2003;21:429-38.
11. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004;4:285-99.
12. Deininger M. Resistance to Imatinib: mechanisms and management. J Natl Compr Canc Netw 2005;3:757-68.
13. Van Etten RA. c-Abl regulation: a tail of two lipids. Curr Biol 2003;13:R608-R610.
14. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
15. Beissert T, Puccetti E, Bianchini A, Guller S, Boehrer S, Hoelzer D, Ottmann OG, Nervi C, Ruthardt M. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003;102:2985-93.
16. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993;13:7587-95.
17. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK, Ren R, Pear WS. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 2002;99:2957-68.
18. Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol 2001;21:840-53.
19. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 2002;9:117-20.
20. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003;12:27-37.
21. Leslie NR, O'Prey J, Bartholomew C, Harrison PR. An activating mutation in the kit receptor abolishes the stroma requirement for growth of ELM erythroleukemia cells, but does not prevent their differentiation in response to erythropoietin. Blood 1998;92:4798-807.
22. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Lanfrancone L, Peschle C, Nolan GP, Pelicci PG. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 1998;58:14-19.
23. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, Boehrer S, Gul H, Schneider O, Ottmann OG, Hoelzer D, Henschler R, et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004;103:3535-43.
24. Grez M, Becker S, Saulnier S, Knoss H, Ott MG, Maurer A, Dinauer MC, Hoelzer D, Seger R, Hossle JP. Gene therapy of chronic granulomatous disease. Bone Marrow Transplant 2000;25(Suppl 2):S99-S104.
25. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26:6082-93.
26. Smith KM, Van Etten RA. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J Biol Chem 2001;276:24372-9.
27. Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000;60:3409-13.
28. O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005;11:6987-93.
29. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
30. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005;105:1652-9.
31. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44.
32. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 2006;103:19466-71.